Virpax Pharmaceuticals, Inc. VRPX

Company Overview

Virpax Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing non-opioid and non-addictive pain management therapies and central nervous system (CNS) treatments. The company operates within the biopharmaceutical and pain management industries, targeting conditions where existing therapies present safety, tolerability, or abuse concerns. Virpax does not currently generate commercial revenue and remains dependent on research and development activities.

The company’s primary value proposition lies in its proprietary drug delivery technologies designed to provide sustained and localized therapeutic effects. Virpax aims to differentiate itself through reformulations of existing drugs using novel delivery mechanisms to improve efficacy, duration, and safety profiles. The company was founded in 2015 and completed its initial public offering in 2020, listing its common stock on the NASDAQ Capital Market under the ticker VRPX.